Hospital-Treated Gram-Negative Infections – Landscape & Forecast – Disease Landscape & Forecast

The rising rates of antimicrobial resistance have created an urgent need for antibiotics with activity against drug-resistant gram-negative pathogens (GNPs). Antibiotics such as carbapenems, which have historically been reserved for later lines of therapy, are being used earlier in treatment, placing additional pressure on the already-limited GNI armamentarium. Despite the launch of novel antibiotics, such as Avycaz / Zavicefta, Zerbaxa, Recarbrio, and Fetroja / Fetcroja, unmet need remains for additional effective treatment options with efficacy in patients with drug-resistant infections, which are associated with high rates of mortality. Although the market is heavily genericized and cost-containment measures have limited commercial success of emerging therapies, innovative approaches like value based pricing (VBP) and de-linked reimbursement models promise to encourage and support future antibiotics' development.

QUESTIONS ANSWERED

  • What impact will the current and emerging antibiotic therapies have on the GNI therapy market? How will ID specialists in different markets make treatment decisions among the emerging therapies in the future?
  • How large are the different GNI indications? What are the resistance rates to different classes of antibiotics across several pathogen species? How will rising antibiotic resistance rates and the entry of new generics shape the market?
  • On what attributes will emerging therapies need to improve to compete with currently marketed products?

Geographies: United States, France, Germany, Italy, Spain, United Kingdom, Japan

Primary Research: More than 20 country-specific interviews with thought-leading infectious disease specialists. Supported by survey data collected for this and other Clarivate research

Epidemiology: Diagnosed events of GNIs segmented by key indications (nosocomial pneumonia, complicated skin and skin structure infections / surgical site infections, bloodstream infections, complicated intra-abdominal infections, urinary tract infections), pathogens (E.coli, Pseudomonas, Acinetobacter, Klebsiella), resistance, and country.

FORECAST: Ten-year, annualized, drug-level sales and patient share of key GNI therapies through 2030, segmented by brands / generics, geography, and five key indications.

Emerging Therapies: Phase III/PR: 7 drugs; Phase I/Phase II: 12 drugs

PRODUCT DESCRIPTION

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary market research.

Table of contents

  • Hospital-Treated Gram-Negative Infections - Landscape & Forecast - Disease Landscape & Forecast
    • Key Updates
      • Q2 2022
        • April 2022
      • Q1 2022
        • March 2022
        • February 2022
        • January 2022
      • Q4 2021
        • December 2021
        • October 2021
      • Q3 2021
        • September 2021
        • August 2021
        • July 2021
      • Q2 2021
        • June 2021
        • May 2021
        • April 2021
    • Key Findings
      • HTGNI - Key Findings
        • June 2021
        • May 2021
        • April 2021
    • Market Outlook
      • Key Findings
        • Market Overview
        • Market Share of Drug Classes for Gram-Negative Infections: 2020
        • Market Share of Drug Classes for Gram-Negative Infections: 2030
        • Hospital-Treated Gram-Negative Infections SWOT Analysis
      • COVID-19: Market Forecast Impact
        • Market Drivers and Constraints
          • What Factors Are Driving the Market for Hospital-Treated Gram-Negative Infections?
          • What Factors Are Constraining the Market for Hospital-Treated Gram-Negative Infections?
        • Drug-Class-Specific Trends
          • Major-Market Sales of Cephalosporins for Hospital-Treated Gram-Negative Infections: 2020-2030
          • Patient Share of Cephalosporins in Hospital-Treated Gram-Negative Infections: 2020-2030
          • Major-Market Sales of Beta-Lactam / Beta-Lactamase Inhibitor Combinations in Hospital-Treated Gram-Negative Infections: 2020-2030
          • Patient Share of Beta-Lactam / Beta-Lactamase Inhibitor Combinations in Hospital-Treated Gram-Negative Infections: 2020-2030
          • Major-Market Sales of Carbapenems for Hospital-Treated Gram-Negative Infections: 2020-2030
          • Patient Share of Carbapenems for Hospital-Treated Gram-Negative Infections: 2020-2030
          • Major-Market Sales of Aminoglycosides for Hospital-Treated Gram-Negative Infections: 2020-2030
          • Patient Share of Aminoglycosides for Hospital-Treated Gram-Negative Infections: 2020-2030
          • Major-Market Sales of Tetracyclines for Hospital-Treated Gram-Negative Infections: 2020-2030
          • Patient Share of Tetracyclines for Hospital-Treated Gram-Negative Infections: 2020-2030
          • Major-Market Sales of Quinolones for Hospital-Treated Gram-Negative Infections: 2020-2030
          • Patient Share of Quinolones for Hospital-Treated Gram-Negative Infections: 2020-2030
      • Forecast
        • Market Forecast Assumptions
        • Market Forecast Dashboard
      • Etiology and Pathophysiology
        • Nosocomial Pneumonia
          • Etiology
          • Pathophysiology
        • Skin and Skin Structure and Surgical-Site Infections
          • Etiology
          • Pathophysiology
        • Urinary Tract Infections
          • Etiology
          • The Urinary System
          • Pathophysiology
        • Intra-Abdominal Infections
          • Etiology
          • Pathophysiology
        • Bloodstream Infections
          • Etiology
          • Pathophysiology
        • Common Gram-Negative Pathogens in Hospital-Treated Infections
          • Enterobacteriaceae
          • Pseudomonads
          • Acinetobacter
        • Common Drug-Resistant Pathogens in Hospital-Treated Infections
          • ESKAPE Pathogens
          • Carbapenem-Resistant Pathogens
          • Quinolone-Resistant Pseudomonas Aeruginosa
          • Third-Generation Cephalosporin-Resistant Klebsiella Pneumoniae
      • Epidemiology
        • Key Findings
          • Epidemiology Populations
            • Disease Definition
            • Methods
            • Sources Used for Diagnosed Events of Hospital-Treated UTIs due to Gram-Negative Pathogens
            • Number of Diagnosed Events of Hospital-Treated UTIs due to Gram-Negative Pathogens in the Major Pharmaceutical Markets: 2020-2030 (Thousands)
            • Disease Definition
            • Methods
            • Sources Used for Diagnosed Events of Hospital-Treated Bloodstream Infections due to Gram-Negative Pathogens
            • Number of Diagnosed Events of Hospital-Treated Bloodstream Infections due to Gram-Negative Pathogens in the Major Pharmaceutical Markets: 2020-2030 (Thousands)
            • Disease Definition
            • Methods
            • Sources Used for Diagnosed Events of Hospital-Treated Nosocomial Pneumonia due to Gram-Negative Pathogens
            • Number of Diagnosed Events of Hospital-Treated Nosocomial Pneumonia due to Gram-Negative Pathogens in the Major Pharmaceutical Markets by Type: 2020-2030 (Thousands)
            • Disease Definition
            • Methods
            • Sources Used for Diagnosed Events of Hospital-Treated cIAIs due to Gram-Negative Pathogens
            • Number of Diagnosed Events of Hospital-Treated cIAIs due to Gram-Negative Pathogens in the Major Pharmaceutical Markets: 2020-2030 (Thousands)
            • Disease Definition
            • Methods
            • Sources Used for Diagnosed Events of Hospital-Treated SSIs and cSSSIs due to Gram-Negative Pathogens
            • Number of Diagnosed Events of Hospital-Treated SSIs and cSSSIs due to Gram-Negative Pathogens in the Major Pharmaceutical Markets: 2020-2030 (Thousands)
            • Percentage Diagnosed
            • Percentage Drug-Treated
            • Number of Diagnosed and Drug-Treated Events of Hospital-Treated UTIs due to Gram-Negative Pathogens in the Major Pharmaceutical Markets: 2020-2030 (Thousands)
            • Number of Diagnosed and Drug-Treated Events of Hospital-Treated BSIs Associated With Gram-Negative Pathogens in the Major Pharmaceutical Markets: 2020-2030 (Thousands)
            • Number of Diagnosed and Drug-Treated Events of Hospital-Treated SSIs and cSSSIs due to Gram-Negative Pathogens in the Major Pharmaceutical Markets: 2020-2030 (Thousands)
            • Number of Diagnosed and Drug-Treated Events of Hospital-Treated Nosocomial Pneumonia due to Gram-Negative Pathogens in the Major Pharmaceutical Markets: 2020-2030 (Thousands)
            • Number of Diagnosed and Drug-Treated Events of Hospital-Treated cIAIs due to Gram-Negative Pathogens in the Major Pharmaceutical Markets: 2020-2030 (Thousands)
            • Methods
            • Sources Used for Diagnosed Events of Hospital-Treated Infections due to Gram-Negative Pathogens
            • Gram-Negative Pathogens Associated With Hospital-Treated Infections in the Major Pharmaceutical Markets: 2020
            • Gram-Negative Pathogens Associated With Hospital-Treated Nosocomial Pneumonia in the Major Pharmaceutical Markets: 2020
            • Disease Definition
            • Methods
            • Sources Used for Antimicrobial Resistance to Extended-Spectrum Cephalosporins
            • Extended-Spectrum Cephalosporin-Resistant Subpopulations
            • Disease Definition
            • Methods
            • Sources Used for Antimicrobial Resistance to Carbapenems
            • Carbapenem-Resistant Subpopulations
            • Disease Definition
            • Methods
            • Sources Used for Antimicrobial Resistance to Fluoroquinolones
            • Fluoroquinolone-Resistant Subpopulations
        • Current Treatment
          • Key Findings
            • Treatment Goals
              • Key Endpoints Used in Clinical Trials for Hospital-Treated Gram-Negative Infections
              • Key Physician Insights on Clinical Endpoints
            • Key Current Therapies
              • Overview
              • Mechanisms of Action of Key Current Drug Classes Used for Hospital-Treated GNIs
              • Current Treatments Used for Hospital-Treated GNIs
              • Market Events Impacting the Use of Key Current Therapies for Hospital-Treated GNIs
              • Comparison of Gram-Negative Pathogen Susceptibility to Select Antibiotics
              • Advantages and Disadvantages of Cephalosporins
              • Ongoing Clinical Development
              • Key Clinical Trials of Cephalosporins for Hospital-Treated GNIs
              • Expert Insight: Cephalosporins
              • Advantages and Disadvantages of Beta-Lactam/Beta-Lactamase Inhibitor Combinations
              • Ongoing Clinical Development
              • Key Clinical Trials of Beta-Lactam / Beta-Lactamase Inhibitor Combinations for Hospital-Treated GNIs
              • Expert Insight: Beta-Lactam / Beta-Lactamase Inhibitor Combinations
              • Advantages and Disadvantages of Carbapenems
              • Expert Insight: Carbapenems
              • Advantages and Disadvantages of Aminoglycosides
              • Expert Insight: Aminoglycosides
              • Advantages and Disadvantages of Tetracyclines
              • Expert Insight: Tetracyclines
              • Advantages and Disadvantages of Quinolones
              • Expert Insight: Quinolones
            • Medical Practice
              • Overview
              • Treatment Guidelines
              • Drug Selection
              • Factors Influencing Drug Selection in Hospital-Treated GNIs
              • Treatment Decision Tree for Hospital-Treated UTIs Caused by GNPs: United States
              • Treatment Decision Tree for Hospital-Treated NP Caused by GNPs: United States
              • Treatment Decision Tree for Hospital-Treated cIAIs Caused by GNPs: United States
              • Treatment Decision Tree for Hospital-Treated BSIs Caused by GNPs: United States
              • Treatment Decision Tree for Hospital-Treated cSSSIs and SSIs Caused by GNPs: United States
              • Urinary Tract Infections
              • Nosocomial Pneumonia
              • Complicated Intra-Abdominal Infections
              • Bloodstream Infections
              • Complicated Skin and Skin Structure Infections and Surgical-Site Infections
              • Treatment Decision Tree for Hospital-Treated UTIs Caused by GNPs: EU5
              • Treatment Decision Tree for Hospital-Treated NP Caused by GNPs: EU5
              • Treatment Decision Tree for Hospital-Treated cIAIs Caused by GNPs: EU5
              • Treatment Decision Tree for Hospital-Treated BSIs Caused by GNPs: EU5
              • Treatment Decision Tree for Hospital-Treated cSSSIs and SSIs Caused by GNPs: EU5
              • Urinary Tract Infections
              • Nosocomial Pneumonia
              • Complicated Intra-Abdominal Infections
              • Bloodstream Infections
              • Complicated Skin and Skin Structure Infections and Surgical-Site Infections
              • Treatment Decision Tree for Hospital-Treated UTIs Caused by GNPs: Japan
              • Treatment Decision Tree for Hospital-Treated NP Caused by GNPs: Japan
              • Treatment Decision Tree for Hospital-Treated cIAIs Caused by GNPs: Japan
              • Treatment Decision Tree for Hospital-Treated BSIs Caused by GNPs: Japan
              • Treatment Decision Tree for Hospital-Treated cSSSIs and SSIs Caused by GNPs: Japan
              • Urinary Tract Infections
              • Nosocomial Pneumonia
              • Complicated Intra-Abdominal Infections
              • Bloodstream Infections
              • Complicated Skin and Skin Structure Infections and Surgical-Site Infections
          • Unmet Need Overview
            • Attainment of Unmet Needs
              • Current Attainment of Unmet Needs in Hospital-Treated Gram-Negative Infections
              • Future Attainment of Unmet Needs in Hospital-Treated Gram-Negative Infections
              • Top Unmet Needs in Hospital-Treated Gram-Negative Infections: Current and Future Attainment
              • Expert Insight on Unmet Needs in Hospital-Treated Gram-Negative Infections
          • Emerging Therapies
            • Key Findings
            • Pipeline Trends for Hospital-Treated Gram-Negative Infections
            • Key Emerging Therapies
              • Key Therapies in Development for Hospital-Treated Gram-Negative Infections
              • Estimated Launch Dates of Key Emerging Therapies for the Treatment of Hospital-Treated Gram-Negative Infections
              • Key Ongoing Clinical Trials of Aztreonam/Avibactam in Gram-Negative Infections
              • Aztreonam/Avibactam Clinical Development
              • Expert Insight: Aztreonam/Avibactam
              • Expectations for Launch and Sales Opportunity of Aztreonam/Avibactam in Hospital-Treated Gram-Negative Infections
              • Key Results From Select Clinical Trials Investigating Cefepime / Enmetazobactam for the Treatment of Gram-Negative Infections
              • Cefepime / Enmetazobactam Clinical Development
              • Expert Insight: Cefepime / Enmetazobactam
              • Expectations for Launch and Sales Opportunity of Cefepime / Enmetazobactam in Hospital-Treated Gram-Negative Infections
              • Cefepime / Taniborbactam Clinical Development
              • Expert Insight: Cefepime / Taniborbactam
              • Expectations for Launch and Sales Opportunity of Cefepime / Taniborbactam in Hospital-Treated Gram-Negative Infections
              • Key Ongoing Clinical Trials of Cefepime / Zidebactam in Gram-Negative Infections
              • Cefepime / Zidebactam Clinical Development
              • Expert Insight: Cefepime / Zidebactam
              • Expectations for Launch and Sales Opportunity of Cefepime / Zidebactam in Hospital-Treated Gram-Negative Infections
              • Key Results From Select Clinical Trials Investigating Sulbactam / Durlobactam for the Treatment of Gram-Negative Infections
              • Sulbactam / Durlobactam Clinical Development
              • Expert Insight: Sulbactam / Durlobactam
              • Expectations for Launch and Sales Opportunity of Sulbactam / Durlobactam in Hospital-Treated Gram-Negative Infections
              • Key Results From Select Clinical Trials Investigating Tebipenem HBr for the Treatment of Gram-Negative Infections
              • Tebipenem HBr Clinical Development
              • Expert Insight: Tebipenem Hbr
              • Expectations for Launch and Sales Opportunity of Tebipenem HBr in Hospital-Treated Gram-Negative Infections
              • Key Results From Select Clinical Trials Investigating Phosphomycins for the Treatment of Gram-Negative Infections
              • Clinical Development
              • Expert Insight: Use of Fosfomycin IV in the Treatment of Gram-Negative Infections
              • Expert Insight: Fosfomycin IV
              • Expectations for Launch and Sales Opportunity of Fosfomycin IV in Hospital Treated Gram-Negative Infections
            • Early-Phase Pipeline Analysis
              • Select Compounds in Early-Phase Development for Hospital-Treated Gram-Negative Infections
            • Nontraditional Therapies
              • Select Nontraditional Therapies in Early-Phase Development for Hospital-Treated Gram-Negative Infections
          • Access and Reimbursement Overview
            • Region-Specific Reimbursement Practices
              • Key Market Access Considerations in Hospital-Treated Gram-Negative Infections in the United States
              • Key U.S. congressional legislation relating to antibiotics
              • General Reimbursement Environment: United States
              • Key Market Access Considerations in Hospital-Treated Gram-Negative Infections in Europe
              • General Reimbursement Environment: EU5
              • Key Market Access Considerations in Hospital-Treated Gram-Negative Infections in Japan
              • General Reimbursement Environment: Japan
          • Appendix
            • Bibliography